Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 16/20 | 0.56 |
| ▸ | AKR1A1 | P14550 | 14/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7755683 | 0.93 | AKR1A1 (0.58) | AKR1B1AKR1A1PTGDR2PTGS1 | |
| SCHEMBL7186763 | 0.90 | AKR1B1 (0.58) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL7751532 | 0.90 | AKR1B1 (0.58) | AKR1B1AKR1A1PTGDR2PTGS1 | |
| SCHEMBL2098715 | 0.87 | AKR1B1 (0.70) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL7188436 | 0.87 | AKR1B1 (0.57) | AKR1B1AKR1A1PTGDR2 | |
| Water SCHEMBL5501664 | 0.87 | AKR1B1 (0.69) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL7951912 | 0.86 | AKR1A1 (0.60) | AKR1B1AKR1A1PTGDR2PTGS1 | |
| SCHEMBL7754413 | 0.85 | AKR1A1 (0.59) | AKR1B1AKR1A1PTGDR2 | |
| SCHEMBL7946639 | 0.84 | AKR1B1 (0.48) | AKR1B1AKR1A1PTGDR2PTGS1 | |
| SCHEMBL2098560 | 0.84 | AKR1B1 (0.58) | AKR1B1AKR1A1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001064205-A2 | COMPOSITIONS CONTAINING A SUBSTITUTED INDOLEALKANOIC ACID AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2001-09-07 | — | — | WO | claimed |
| US-6964980-B2 | Method of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substitute indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| US-20030216452-A1 | Method of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substitute indolealkanoic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, INC. | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216452-A1 | Method of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substitute indolealkanoic acids | LIPG, PNLIP, LIPA | AKR1B1 475/4885AKR1A1 513/4885PTGDR2 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.